Mivebresib is a BET inhibitor with potential antineoplastic activity. It disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo. Mivebresib is also a MYC and the TMPRSS2-ETS fusion proteins inhibitor. Mivebresib can inhibit cell growth in susceptible tumors.
Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | BET Bromodomain
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye